Majrashi, A.; Gue, Y.X.; Shantsila, A.; Williams, S.; Lip, G.Y.H.; Pettitt, A.R.
Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study. J. Clin. Med. 2024, 13, 7492.
https://doi.org/10.3390/jcm13237492
AMA Style
Majrashi A, Gue YX, Shantsila A, Williams S, Lip GYH, Pettitt AR.
Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study. Journal of Clinical Medicine. 2024; 13(23):7492.
https://doi.org/10.3390/jcm13237492
Chicago/Turabian Style
Majrashi, Abdulrahman, Ying X. Gue, Alena Shantsila, Stella Williams, Gregory Y. H. Lip, and Andrew R. Pettitt.
2024. "Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study" Journal of Clinical Medicine 13, no. 23: 7492.
https://doi.org/10.3390/jcm13237492
APA Style
Majrashi, A., Gue, Y. X., Shantsila, A., Williams, S., Lip, G. Y. H., & Pettitt, A. R.
(2024). Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study. Journal of Clinical Medicine, 13(23), 7492.
https://doi.org/10.3390/jcm13237492